Extracorporeal shockwave therapy in musculoskeletal disorders

• Published in: Journal of orthopaedic surgery and research Vol. 7; no. 1; p. 11
• Main Author: Wang, Ching-Jen
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.03.2012; BioMed Central; BMC
• Subjects: Animals; Bone density; Bone surgery; Care and treatment; Experiments; Extracorporeal shockwave therapy; Fasciitis, Plantar - therapy; FDA approval; Federal regulation; Femur Head Necrosis - therapy; Fracture Healing - radiation effects; Fractures, Ununited - therapy; Gene therapy; High-Energy Shock Waves - therapeutic use; Hip joint; Humans; Lithotripsy; Lupus; Medical research; Musculoskeletal diseases; Musculoskeletal Diseases - therapy; Musculoskeletal disorders; Orthopedics; Pain; Placebo effect; Pressure distribution; Review; Studies; Tendinopathy - therapy
• ISSN: 1749-799X; 1749-799X
• DOI: 10.1186/1749-799X-7-11

The sources of shockwave generation include electrohydraulic, electromagnetic and piezoelectric principles. Electrohydraulic shockwaves are high-energy acoustic waves generated under water explosion with high voltage electrode. Shockwave in urology (lithotripsy) is primarily used to disintegrate urolithiasis, whereas shockwave in orthopedics (orthotripsy) is not used to disintegrate tissues, rather to induce tissue repair and regeneration. The application of extracorporeal shockwave therapy (ESWT) in musculoskeletal disorders has been around for more than a decade and is primarily used in the treatment of sports related over-use tendinopathies such as proximal plantar fasciitis of the heel, lateral epicondylitis of the elbow, calcific or non-calcific tendonitis of the shoulder and patellar tendinopathy etc. The success rate ranged from 65% to 91%, and the complications were low and negligible. ESWT is also utilized in the treatment of non-union of long bone fracture, avascular necrosis of femoral head, chronic diabetic and non-diabetic ulcers and ischemic heart disease. The vast majority of the published papers showed positive and beneficial effects. FDA (USA) first approved ESWT for the treatment of proximal plantar fasciitis in 2000 and lateral epicondylitis in 2002. ESWT is a novel non-invasive therapeutic modality without surgery or surgical risks, and the clinical application of ESWT steadily increases over the years. This article reviews the current status of ESWT in musculoskeletal disorders.